Early trial results suggest tocilizumab significantly improves outcomes for critically ill COVID-19 patients
The rheumatoid arthritis drug tocilizumab significantly improves outcomes for critically ill patients with severe COVID-19, early findings from the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia have suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
More News: Actemra | Arthritis | COVID-19 | Drugs & Pharmacology | Pneumonia | Rheumatoid Arthritis | Rheumatology